Bcl-2 Antibody (E17)

Product Discontinued

Bcl-2 Antibody (E17) Summary

• Immunogen: A synthetic peptide corresponding to residues between BH3 and BH4 of human Bcl-2 was used as immunogen.
• Localization: Endoplasmic reticulum, outer mitochondrial membrane and intracellular membrane of the nuclear envelope.
• Specificity: The antibody does not cross-react with other Bcl-2 family members
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: BCL2
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:200
  • Immunocytochemistry/ Immunofluorescence 1:200
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:100-1:200
  • Immunoprecipitation 1:50
  • Western Blot 1:1000-1:10000
• Application Notes: This is a high affinity, high titer antibody. Optimal dilutions should be determined by the end user. (Provided dilutions serve only as a suggestive starting point.)
• Theoretical MW: 26 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  Jurkat Whole Cell Lysate
  MCF-7 Whole Cell Lysate

Reactivity Notes

Species cross reactivity tested by Western Blot only.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Culture supernatant in buffered aqueous solution
• Preservative: No Preservative
• Concentration: 0.01 mg/ml
• Purity: Protein A or G purified

Alternate Names for Bcl-2 Antibody (E17)

• apoptosis regulator Bcl-2
• B-cell CLL/lymphoma 2
• Bcl2
• Bcl-2

Background

The Bcl-2 family of proteins regulate apoptosis by controlling mitochondrial permeability and release of cytochrome c. Bcl-2 is an anti-apoptotic protein that resides in the outer mitochondrial wall and inhibits release of cytochrome c (1). Over-expression of Bcl-2 has been shown to promote cell survival by suppressing apoptosis. It has been documented that bcl-2 becomes deregulated in tumor cells as a result of translocation into the immunoglobulin heavy-chain locus and is therefore activated in B cell malignancies (2). It has also been shown that post-translational modification of Bcl-2, phosphorylation at serine 70, may be required to render its full and/or enhanced anti-apoptotic effect (3, 4).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Bcl-2 Antibody (NB110-55551)(15)

Publications using NB110-55551

• Ozsobacı NP, Ergun DD, Tuncdemir M, OzCelik D Protective Effects of Zinc on 2.45 GHz Electromagnetic Radiation-Induced Oxidative Stress and Apoptosis in HEK293 Cells Biol Trace Elem Res 2019-07-17 [PMID: 31317470] (IF/IHC, Human)
• May KL, Paton JC, Paton AW et al. Escherichia coli subtilase cytotoxin induces apoptosis regulated by host Bcl-2 family proteins Bax/Bak. Infect Immun 2010-11-01 [PMID: 20713620] (WB)
• Yecies D, Carlson NE, Deng J et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010-04-01 [PMID: 20197552] (WB)
• Idikio HA et al. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol 2009-11-01 [PMID: 20126585]
• Priault M, Hue E, Marhuenda F et al. Differential dependence on Beclin 1 for the regulation of pro-survival autophagy by Bcl-2 and Bcl-xL in HCT116 colorectal cancer cells. PLoS One 2010-01-01 [PMID: 20090905] (IP)
• Steinacker P, Hawlik A, Lehnert S et al. Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. Am J Pathol 2010-03-01 [PMID: 20075202] (WB)
• Winkler J, Martin-Killias P, Pluckthun A et al. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009-09-01 [PMID: 19723880] (WB)
• Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009-10-01 [PMID: 19704118] (WB)
• Johnson NA, Savage KJ, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009-09-01 [PMID: 19597184] (IF/IHC)
• Bai Y, Meng Z, Cui M et al. An Ang1-Tie2-PI3K axis in neural progenitor cells initiates survival responses against oxygen and glucose deprivation. Neuroscience 2009-05-01 [PMID: 19409199] (WB)
• Eliseev RA, Malecki J, Lester T et al. Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect. J Biol Chem 2009-04-01 [PMID: 19228691] (IP)
• Kornasio R, Riederer I, Butler-Browne G et al. Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim Biophys Acta 2009-05-01 [PMID: 19211028] (ICC/IF)
• Masir N, Campbell LJ, Goff LK et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009-03-01 [PMID: 19120369] (WB)
• Eliseev RA, Dong YF, Sampson E et al. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 2008-06-01 [PMID: 18223689] (WB)
• Deng J, Carlson N, Takeyama K et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007-08-01 [PMID: 17692808] (IP)

Bioinformatics

• Gene Symbol: BCL2
• Entrez:
  • 596(Human)
  • 12043(Mouse)
  • 24224(Rat)
• Uniprot:
  • P10415()